To date, there is very limited and underpowered data on the efficacy of α2δ ligands in the treatment of abdominal pain in patients with IBS, and thus a critical need for larger multi‐centre, double‐blind, randomised, placebo‐controlled trials to determine their true clinical utility. The gene discussed is ATXN2L; the disease is irritable bowel syndrome.